

Appointment of Chief Executive Officer

Neurotech International Limited (ASX: NTI) ("Neurotech" "NTI" or "the Company") is pleased to announce the appointment of Dr Alexandra Andrews as Chief Executive Officer, effective from 8th March 2022.

Dr Andrews holds a Doctor of Philosophy (PhD) in Neuroscience from the University of Western Australia. She brings expertise in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.

Previously, she was Director of Operations at NeuroScientific Biopharmaceuticals Ltd. Throughout her career, Dr Andrews has worked closely with clinical researchers, investors and entrepreneurs, providing scientific and strategic input into clinical development plans and overseeing manufacturing. She brings commercial, transactional and project management experience, including via her earlier role at Linear Clinical Research where she focused on attracting partnerships with US biotechnology and pharmaceutical companies, and managing trial logistics.

"I am very pleased to have an executive and a scientist of Dr Andrews' stature join Neurotech. She comes on board at a pivotal point - just ahead of the results release from our Phase I/II clinical studies in children with Autism Spectrum Disorder," said Brian Leedman, Chairman of Neurotech International. "Alex has worked with me previously and her appointment will further strengthen management's scientific and commercial leadership experience as the Company progresses with the development of unique cannabis strains for the treatment of neurological disorders".

Dr Andrews said, "I am delighted to be joining Neurotech International as CEO at this exciting time as clinical research into Neurotech's low level THC cannabis plant strains is unfolding - initially in children with Autism, then in other neurological and inflammatory disorders. I am passionate about improving patient outcomes and am looking forward to collaborating with the team in leveraging NTI's novel technology to accelerate advancements in health and medicine."

A summary of the key terms of Dr Andrews' appointment is set out as part of Annexure A.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Brian Leedman
Chairman
b.leedman@neurotechinternational.com
+61 (0)41 228 1780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 (0)41 066 7844

Media:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
+61 (0)411 117 774

About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>

Annexure A

Summary Key Terms of CEO Appointment – Dr Alexandra Andrews

Term	<p>Dr Andrews' appointment as Chief Executive Officer ("CEO") will become effective on 8th March 2022 ("Commencement Date").</p> <p>Dr Andrews' appointment may be terminated by either party without cause by giving no less than three months' notice.</p>
Services	<p>Dr Andrews has been engaged to provide those services usually required of a Chief Executive Officer of a Company of the scale and nature of NTI, including the executive leadership and management of the Group.</p>
Remuneration	<p>Dr Andrews will be paid a base salary of \$250,000 per annum inclusive of superannuation ("Base Salary").</p> <p>In addition, it is proposed that the Company will issue of the following securities to Dr Andrews (or her nominee):</p> <ul style="list-style-type: none"> • 5,000,000 Unlisted Options, with an exercise price of \$0.08 and expiry date two years from the date on which the Options are first issued, which will vest 12 months after the Commencement Date provided Dr Andrews remains continually employed by the Company as CEO for the entire year; • 5,000,000 Unlisted Options, with an exercise price of \$0.12 and expiry date two years from the date on which the Options are first issued, which will vest 18 months after the Commencement Date provided Dr Andrews remains continually employed by the Company as CEO for the entire 18 months period. • 5,000,000 Unlisted Options, with an exercise price of \$0.16 and expiry date two years from the date on which the Options are first issued, which will vest two years after the Commencement Date provided Dr Andrews remains continually employed by the Company as CEO for the entire two year period.